Arrien Pharmaceuticals begins Phase I trial of ARN-6039 to treat multiple sclerosis

US-based drug-development company Arrien Pharmaceuticals has begun its Phase I clinical trial of ARN-6039 to treat relapse, remitting, and progressive multiple sclerosis (MS), an autoimmune neuroinflammatory demyelinating disease of the central nervo…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news